Australia markets closed

OTLK Jun 2024 5.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.15000.0000 (0.00%)
At close: 10:43AM EDT
Full screen
Previous close2.1500
OpenN/A
Bid2.0500
Ask3.2000
Strike5.00
Expiry date2024-06-21
Day's range2.1500 - 2.1500
Contract rangeN/A
VolumeN/A
Open interest4
  • GlobeNewswire

    Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

    Live video webcast on Tuesday, June 18th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET. As part of the event, Russell Trenary, President and Chief Executi

  • GlobeNewswire

    Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

    LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMDEuropean Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, Norway and LiechtensteinLYTENAVA™ (bevacizumab gamma) receives ten years of market exclusivity in EUAdvancing toward commercial launch of LYTENAVA™ (bevacizumab gamma) in EU expected in calendar Q1 2025Strategic partner

  • Thomson Reuters StreetEvents

    Q2 2024 Outlook Therapeutics Inc Earnings Call

    Q2 2024 Outlook Therapeutics Inc Earnings Call